Nectar Lifesciences Ltd

Key AGM outcomes

• 31st AGM held Sept 18, 2026 via VC/OAVM with remote e-voting Sept 15–17 and Insta Poll.
• Statutory and Secretarial audits issued unqualified opinions for 2025-26.
• Stand-alone financial statements for year ended March 31, 2026 adopted.
• Mr. Sanjiv Goyal to be re-appointed as Director, retiring by rotation.
• Dr. Kuldip Kumar Bhasin re-appointed as Independent Director for second term.
• Dr. Indu Pal Kaur re-appointed as Independent Director for second term.
• Dr. Gunmala Suri appointed as Non-Executive Non-Independent Director.
• KFin Technologies Limited appointed as Registrar and Transfer Agent for e-voting.
• Voting results to be notified to exchanges within two working days.

AGM Details

• 31st AGM held on 18 Sep 2026; remote e-voting and Insta Poll; cut-off date 11 Sep 2026.

Key Resolutions

• Adoption of standalone and consolidated financial statements for year ended March 31, 2026.
• Re-appointment of Mr. Sanjiv Goyal as Director by rotation.
• Re-appointment of Dr. Kuldip Kumar Bhasin as Independent Director for second term.
• Re-appointment of Dr. Indu Pal Kaur as Independent Director for second term.
• Appointment of Dr Gunmala Suri as Non-Executive Non-Independent Director.

Voting Results

• Resolution 1: Passed; overwhelming approval with approx 99.97% in favour.
• Resolution 2: Passed; similar high approval.
• Resolution 3: Special, Passed; very high approval.
• Resolution 4: Special, Passed; very high approval.
• Resolution 5: Passed; high approval.

Dividend

• No dividend proposed or declared.

Director Changes

• Sanjiv Goyal re-appointed by rotation.
• Dr Kuldip Kumar Bhasin re-appointed for second term.
• Dr Indu Pal Kaur re-appointed for second term.
• Dr Gunmala Suri appointed as Non-Executive Non-Independent Director.

AGM Proceedings Summary

• 31st AGM held Sept 18, 2026 at 11:00 IST via VC/OAVM.
• Cut-off date for voting: Sept 12, 2026; remote e-voting Sept 15–17, 2026.
• Two independent directors re-appointed for a second five-year term.
• Dr. Gunmala Suri appointed as Non-Executive Non-Independent Director.
• Statutory auditors issued unqualified opinion for FY2025-26.
• Voting results to stock exchanges within two working days and uploaded on company and KFin sites.
• KFin Technologies Limited appointed as RTA to provide e-voting facility.
• Ordinary: Adoption of Standalone and Consolidated Financial Statements for year ended 31 March 2026.
• Ordinary: Re-appointment of Mr. Sanjiv Goyal by rotation.
• Special: Re-appointment of Dr. Kuldeep Kumar Bhasin as Independent Director for second term.
• Special: Re-appointment of Dr. Indu Pal Kaur as Independent Director for second term.
• Ordinary: Appointment of Dr. Gunmala Suri as Non-Executive Non-Independent Director.

AGM details and notice access

• 31st AGM to be held on 18 September 2026 at 11:00 IST via VC/OAVM.
• Remote e-voting from 9:00 IST on September 15, 2026 to 17:00 IST on September 17, 2026.
• Cut-off date for AGM and e-voting is September 11, 2026.
• Electronic copies of AGM Notice and Annual Report 2025-26 have been sent to registered emails.
• Shareholders without registered email addresses can access via provided web links.
• Weblinks for AGM Notice and Annual Report are on company and exchange sites.
• To register email addresses, approach your DP for demat holdings or RTA for physical shares.
• KFin Technologies contact details provided for registration and evoting assistance.

Financials overview

• Standalone revenue from operations: nil for FY26.
• Standalone other income: INR 92.91 million.
• Standalone profit before tax (continuing): INR -878.70 million.
• Standalone tax expense: INR 305.29 million.
• Standalone PAT after tax: INR -573.41 million.
• Discontinued operations: slump sale gain INR 1,633.73 million.
• Discontinued PAT: INR -2,355.44 million.
• Total PAT for the year: INR -2,928.85 million.
• Consolidated revenue (incl. discontinued): INR 4,709.75 million.

Restructuring and monetization

• Slump sale of Pharma businesses to Ceph completed Nov 10, 2025.
• Final consideration from BTA: INR 12,539.86 million.
• Exceptional gain from slump sale: INR 1,633.73 million.
• Menthol assets sold to Ceph for INR 200 million.
• Capsule EHGC business slump sale to Capnest for INR 199 million.
• Capsule assets classified as held for sale; sale pending completion.
• Jammu unit assets held for sale: INR 17.61 million.
• Garhshankar land held for sale: INR 132.16 million.
• MOA amended to include real estate; AEPL acquired March 6, 2026.

Capital structure & shareholding

• Buyback of 30,000,000 equity shares at INR 27 per share.
• Total buyback amount INR 810 million; premium of INR 780 million to Securities Premium.
• Paid-up capital reduced by INR 30 million to INR 194.26 million.
• Promoter holdings: Sanjiv Goyal 24.63%, Sanjiv HUF 22.46%, Raman Goyal 4.76%.
• Total outstanding shares reduced to 19,42,60,970.

Real estate pivot and subsidiaries

• Object clause amended to include real estate activities.
• Acquired Avensis Exports Private Limited as a wholly owned subsidiary (AEPL) on Mar 6, 2026.
• AEPL transaction forms part of diversification into real estate.

Dividends and CSR

• Dividend for FY25-26 not declared.
• CSR expenditure FY25-26: INR 2.08 million; administrative and other costs: NIL.
• Excess CSR spend of INR 6.76 million recognized as an asset.

Governance and audit

• Auditors: Deepak Jindal & Co; unmodified opinion; no material qualifications.
• Secretarial auditor: Prince Chadha; no qualifications.
• Nine board meetings held in FY2025-26.

Cash flow and liquidity

• Net cash from operating activities (standalone): INR -4,173.52 million.
• Net cash from investing activities: INR -12,054.11 million.
• Net cash from financing activities: INR -6,991.48 million.
• Cash and cash equivalents year-end: INR 1,121.35 million.

Related party & intercompany

• Inter-corporate loan to AEPL: INR 980.00 million; interest 6.71 million.
• Remuneration to KMP and relatives totaled INR 30.27 million.

Outlook and risk factors

• Strategic shift to real estate; evaluating residential/commercial projects.
• Risks include regulatory approvals, land/title issues, inflation, interest rates, liquidity.

Key financial indicators (at a glance)

• Consolidated total assets: INR 6,216.06 million.
• EPS (basic) – continuing operations: INR -2.62.
• Promoter stake: 24.63% (Sanjiv Goyal).
• Shares outstanding (year-end): 19,42,60,970.

AGM details

• 31st Nectar Lifesciences AGM on Sep 18, 2026 at 11:00 IST via VC/OAVM.
• Remote e-voting from 9:00 AM on Sep 15 to 5:00 PM on Sep 17, 2026.
• Cut-off for voting eligibility: Sep 11, 2026.
• Register of Members and share transfer books closed Sep 12–18, 2026.

Key resolutions

• Ordinary: Adopt Standalone and Consolidated financial statements for year ended Mar 31, 2026.
• Ordinary: Re-appointment of Mr. Sanjiv Goyal as director, by rotation.
• Special: Re-appointment of Dr. Kuldip Kumar Bhasin as Independent Director for second five-year term.
• Special: Re-appointment of Dr. Indu Pal Kaur as Independent Director for second five-year term.
• Ordinary: Appointment of Dr. Gunmala Suri as Non-Executive Non-Independent Director, effective Aug 15, 2026.

Remuneration / board actions

• Dr. Gunmala Suri to receive sitting fees for attending meetings.

Voting status

• Voting results not disclosed in the notice.

Dividend

• No dividend proposed or declared; unclaimed 2018-19 dividends to be transferred to IEPF.

Director changes

• Gunmala Suri appointed Additional Director on Aug 15, 2026; to be appointed NED.
• Sanjiv Goyal to continue as director by rotation.

Corporate office address update

• New corporate office: Godrej Eternia, West Wing (Tower A), Plot No. 70, Industrial Area, Phase-1, Chandigarh 160 002.
• Effective date: September 15, 2026.